FMC-376 vs Sotorasib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: KRAS G12C · full Non-Small Cell Lung Cancer pipeline
FMC-376
Developed by Frontier Medicines Corporation
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: October 2027 · NCT06244771 (registry estimate)
No aligned efficacy figure on record for this race.
Sotorasib
Marketed by Amgen and partners
NCT04303780 · Phase 3 · completed
The 345 participants were randomized 1:1 to sotorasib or active-comparator docetaxel, but treatment assignment was not masked. The primary clinical endpoint, progression-free survival assessed by blinded independent central review, was met in favor of sotorasib, with median progression-free survival of 5.62 versus 4.47 months and a hazard ratio of 0.663 (p=0.002).
Next expected readout: November 2026 · NCT06249282 (registry estimate)
Reported efficacy
Progression-free Survival (PFS) (Baseline up to primary analysis data cut-off date (02 August 2022); max time on study as of primary analysis data cut off was 24.3 months): Progression-free Survival (PFS) (Baseline up to primary analysis data cut-off date (02 August 2022); max time on study as of primary analysis data cut off was 24.3 months): AMG 510 5.62 months (95% CI 4.27 to 7.75) vs Docetaxel 4.47 months (95% CI 3.02 to 5.68) (met)
Result source: NCT04303780
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | FMC-376 | Sotorasib |
|---|---|---|
| PFS, median | —Not reported | 5.6 vs 4.5vs DocetaxelNCT043037802 other results
|
| OS, median | —Not reported | 12.4bNCT050547251 other result
|
| ORR | —Not reported | —Trial running · NCT06497556 |
| Duration of response, median | —Not reported | 12.2bNCT05054725 |
PFS, median
- FMC-376
- —Not reported
- Sotorasib
- 5.6 vs 4.5vs DocetaxelNCT04303780
2 other results
- 7.7 NCT05054725
- 2.6 NCT05054725
OS, median
- FMC-376
- —Not reported
- Sotorasib
- 12.4bNCT05054725
1 other result
- 5.8 NCT05054725
ORR
- FMC-376
- —Not reported
- Sotorasib
- —Trial running · NCT06497556
Duration of response, median
- FMC-376
- —Not reported
- Sotorasib
- 12.2bNCT05054725
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
FMC-376: no structured comparison results are available for Non-Small Cell Lung Cancer.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. FMC-376: 0 of 4 rows · Sotorasib: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Sotorasib |
|---|---|
| Dropout rate | 100%a NCT04303780 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 3 more results—200 mg BIW D1D2 + 960 mg QD NCT05054725 · Phase 2 · registry result, not featured evidence · combination 93%200 mg D1D2 + 960 mg QD NCT05054725 · Phase 2 · registry result, not featured evidence · combination 100%140 mg BIW D1D2 + 960 mg QD NCT05054725 · Phase 2 · registry result, not featured evidence · combination |
| Discontinued due to AEs | —a NCT04303780 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 3 more results—200 mg BIW D1D2 + 960 mg QD NCT05054725 · Phase 2 · registry result, not featured evidence · combination —200 mg D1D2 + 960 mg QD NCT05054725 · Phase 2 · registry result, not featured evidence · combination —140 mg BIW D1D2 + 960 mg QD NCT05054725 · Phase 2 · registry result, not featured evidence · combination |
| Serious AEs | 53.8%a NCT04303780 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 3 more results100%200 mg BIW D1D2 + 960 mg QD NCT05054725 · Phase 2 · registry result, not featured evidence · combination —200 mg D1D2 + 960 mg QD NCT05054725 · Phase 2 · registry result, not featured evidence · combination 75%140 mg BIW D1D2 + 960 mg QD NCT05054725 · Phase 2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | a diarrhoea 41.4% nausea 25.4% decreased appetite 23.1% NCT04303780 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 2 more results200 mg BIW D1D2 + 960 mg QD diarrhoea 62.8% alanine aminotransferase increased 46.5% aspartate aminotransferase increased 44.2% NCT05054725 · Phase 2 · registry result, not featured evidence · combination 140 mg BIW D1D2 + 960 mg QD alanine aminotransferase increased 75% aspartate aminotransferase increased 75% diarrhoea 75% NCT05054725 · Phase 2 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for 3 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Sotorasib
show 1 more result
show 1 more result
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: FMC-376's landscape · Sotorasib's landscape